Please login to the form below

Not currently logged in
Email:
Password:

Gilead reports positive data on 'universal' hepatitis C regimen

Sets sights on regulatory approval for combination therapy 
Gilead

A combination of Gilead Sciences hepatitis C virus (HCV) drug Sovaldi with a new compound can provide high cure rates regardless of the strain of the virus infecting the patient.

The once-daily, fixed-dose combination of Sovaldi (sofosbuvir) with velpatasvir (GS-5816) - described as a 'pan-genotypic' NS5A inhibitor - could eliminate the need for HCV patients to have a genotyping test before starting treatment, said the company.

Four phase III trials of the drug (ASTRAL 1-4) have now been completed, spanning patients with HCV genotypes 1 to 6 and including some with established liver cirrhosis, and showed sustained virologic response (SVR) rates ranging from 80% to 100% after 12 weeks' treatment.

Genotype 1 is the most common form worldwide, making up around half of the 185m cases - add in genotypes 2 and 3 and around 60% of HCV infections are accounted for. However, given the huge number of HCV cases the less common genotype infections still affect millions of people, often living in lower-income countries and these are much less served in terms of drug options.

Gilead is planning to file for approval of the new combination in the US and Europe before the end of the year, and is hoping for a rapid review as the drug has already been granted a 'breakthrough' designation by the FDA.

If approved, the new drug will join Sovaldi and Harvoni (sofosbuvir/ledipasvir), a product specifically indicated for patients with HCV genotype 1 infection, the Gilead's HCV portfolio. The two products brought in sales of $2.26bn and $7.19bn respectively in the first six months of the year, well ahead of expectations and new rivals such as AbbVie's Viekira Pak (ombitasvir/paritaprevir/ritonavir and dasabuvir) which turned over $616m in the same period.

"The ASTRAL study results demonstrate that a 12-week course of therapy with the first fixed-dose combination of two pan-genotypic compounds can provide high cure rates for patients with all HCV genotypes," said Gilead's chief scientific officer Norbert Bischofberger.

Gilead recently presented data on a triple combination of sofosbuvir, velpatasvir and pan-genotypic protease inhibitor GS which indicated that therapy could allow treatment duration to be reduced to six or eight weeks. The triple regimen is currently in two phase II studies.

Article by
Phil Taylor

22nd September 2015

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
dna Communications

Healthcare communications with unique thinking, insight and attitude...

Latest intelligence

Pharma index map
The 2019 CPhI Pharma Index Report
Examining this year’s industry performance...
Five key trends in precision and personalised healthcare
Here, we deep dive into five of the key trends in precision medicine and personalised healthcare to explore how the healthcare industry is changing and how pharmaceutical and biotech companies...
OPEN Health Graduate Programme: from OPEN VIE to OPEN Health Medical Communications
Isobel Owens shares her experience of the OPEN Health Graduate Programme from OPEN VIE to OPEN Health Medical Communications...

Infographics